Table 5 Summary statistics for the TNAS v3.0 and CIPN20 subscales at the initial assessment, by cohort
Treatment Groups | ||||
|---|---|---|---|---|
Bortezomib n = 20 | Oxaliplatin n = 20 | Taxane–Platinum n = 20 | p-value* | |
TNAS V3.0 | Mean (SD) | Mean (SD) | Mean (SD) | |
TNAS global | 2.90 (1.51) | 3.10 (2.09) | 4.60 (2.56) | 0.026 |
TNAS sensory | 3.13 (1.63) | 3.34 (2.04) | 4.84 (2.55) | 0.025 |
TNAS interference | 2.40 (2.04) | 2.62 (2.5) | 4.13 (2.97) | 0.070 |
EORTC-CIPN20** | ||||
CIPN20 sensory | 17.15 (4.74) | 18.05 (5.48) | 19.85 (7.03) | 0.336 |
CIPN20 motor | 13.45 (4.11) | 12.95 (3.65) | 14.35 (6.40) | 0.656 |
CIPN20 autonomic | 3.80 (1.4) | 3.90 (1.37) | 3.20 (1.40) | 0.236 |